Literature DB >> 17387551

Role of biomarkers in developing new therapies for vascular disease.

Vijay Nambi1, Christie M Ballantyne.   

Abstract

BACKGROUND: The use of biomarkers has been among the advances that have helped in the better medical management of patients. Biomarkers such as total cholesterol, low-density lipoprotein cholesterol, and hemoglobin A1c are used routinely. Advances in technologies, proteomics, and genomics and the resultant improved understanding of the pathophysiology of vascular diseases have led to the identification of several promising biomarkers. These biomarkers may be used to identify specific populations that may benefit from therapies, as surrogate markers of clinical efficacy, or as targets of therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387551     DOI: 10.1007/s00268-006-0712-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  34 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

Review 2.  Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-11-11       Impact factor: 29.690

3.  C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.

Authors:  W Koenig; M Sund; M Fröhlich; H G Fischer; H Löwel; A Döring; W L Hutchinson; M B Pepys
Journal:  Circulation       Date:  1999-01-19       Impact factor: 29.690

4.  C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.

Authors:  T P Zwaka; V Hombach; J Torzewski
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

5.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

6.  Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis.

Authors:  M T Quinn; S Parthasarathy; D Steinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

7.  Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

Authors:  K L Carpenter; I F Dennis; I R Challis; D P Osborn; C H Macphee; D S Leake; M J Arends; M J Mitchinson
Journal:  FEBS Lett       Date:  2001-09-21       Impact factor: 4.124

8.  Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases.

Authors:  Y Zhu; J H Lin; H L Liao; L Verna; M B Stemerman
Journal:  Biochim Biophys Acta       Date:  1997-03-10

9.  Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Lloyd E Chambless; Merle Myerson; Kenneth K Wu; A Richey Sharrett; Eric Boerwinkle
Journal:  Arch Intern Med       Date:  2005-11-28

10.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

Authors:  C J Packard; D S O'Reilly; M J Caslake; A D McMahon; I Ford; J Cooney; C H Macphee; K E Suckling; M Krishna; F E Wilkinson; A Rumley; G D Lowe
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

View more
  1 in total

Review 1.  Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins.

Authors:  Thomas D Giles; Gary E Sander; Bobby D Nossaman; Philip J Kadowitz
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-04       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.